Compare CRC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRC | DNTH |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | 2500 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.5B |
| IPO Year | N/A | 2018 |
| Metric | CRC | DNTH |
|---|---|---|
| Price | $52.59 | $95.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $72.57 | ★ $121.00 |
| AVG Volume (30 Days) | 772.3K | ★ 1.3M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | $12.37 | N/A |
| Revenue Next Year | N/A | $29.48 |
| P/E Ratio | $13.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $43.25 | $18.08 |
| 52 Week High | $71.98 | $96.78 |
| Indicator | CRC | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 33.34 | 60.28 |
| Support Level | $44.99 | $79.27 |
| Resistance Level | $63.65 | N/A |
| Average True Range (ATR) | 1.83 | 5.49 |
| MACD | -0.30 | 1.53 |
| Stochastic Oscillator | 19.41 | 84.67 |
California Resources Corp is an independent oil and natural gas exploration and production company. The company has operations spread across different properties in several oil and gas exploration basins in California and Utah, such as the Midway-Sunset, South Belridge, and McKittrick fields, in the San Joaquin Basin, and other properties located in Los Angeles, Sacramento, Uinta, and the Ventura and Salinas basins. Additionally, the company is focused on maximizing the value of its land, mineral ownership, and energy expertise for decarbonization by developing carbon capture and storage (CCS) and other emissions-reducing projects. Its business is organized into two reporting segments: oil and natural gas, which generate maximum revenue, and carbon management.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.